In this episode of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, discusses the how and why of making precise clinical diagnosis of neurodegenerative diseases with Russ Lebovitz, MD, PhD, co-founder and CEO of Amprion.

Among the topics they discuss:

• The critical importance of making accurate diagnoses of neurodegenerative diseases
• Why alpha-synuclein is an accurate biomarker for a number of degenerative diseases, including Alzheimer’s
• How adding neurodegenerative testing to the routine diagnostic menu would benefit patients and their caregivers
• Why we’re entering a neurological healthcare “golden age”

In this episode of Clinical Lab Chat, CLP Director of Business Intelligence Chris Wolski engages in a wide-ranging discussion with Peggy Lillis Foundation CEO and founder Christian Lillis about the organization’s efforts to raise awareness of C diff. Among the topics they discuss:

• Why C diff is difficult to diagnose
• How Peggy Lillis is engaging with the public, scientific community, and legislators to improve understanding, diagnostics, and treatment of this increasingly common disease
• The parallels of these awareness efforts with other public health education efforts
• How laboratorians can help their organizations develop workflows to avoid under- and over-testing for C diff.

In this episode of Clinical Lab Chat, Jeff Andrews, MD, FRCSC, BD’s VP of Global Medical Affairs for Diagnostic Solutions, makes a return visit to the studio for a conversation with CLP’s director of business intelligence, Chris Wolski, about BD and MD Anderson’s collaboration on HPV sample self-collection study.

Among the topics they cover:

• How self-collection aids in the fight against cervical cancer
• The importance of reaching underserved communities
• How MD Anderson’s program is shining a light on the need for sampling options in the U.S. and across the world
• The business benefits self-collection brings to labs
• The impact self-collection will have in the near- and long-term